| Description | Daglutril, a NEP/ECE inhibitor, is potentially used for the treatment of hypertension, heart failure andpulmonary. Daglutril inhibits systemic conversion of big endothelin-1 in humans. |
| Synonyms | SLV306, SLV 306, SLV-306 |
| molecular weight | 534.64 |
| Molecular formula | C31H38N2O6 |
| CAS | 182821-27-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16(15):2283-92. doi: 10.1517/14656566.2015.1079623. Epub 2015 Sep 7. Review. PubMed PMID: 26389772. 2. Maguire JJ, Davenport AP. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol. 2014 Dec;171(24):5555-72. doi: 10.1111/bph.12874. Epub 2014 Nov 24. Review. PubMed PMID: 25131455; PubMed Central PMCID: PMC4290702. 3. Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P; Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Sep;1(1):19-27. doi: 10.1016/S2213-8587(13)70029-9. Epub 2013 Jun 13. PubMed PMID: 24622263. 4. Laurent S. Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope? Lancet Diabetes Endocrinol. 2013 Sep;1(1):2-3. doi: 10.1016/S2213-8587(13)70036-6. Epub 2013 Jun 13. PubMed PMID: 24622251. |